TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01488214

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic resonance Imaging
Description: Magnetic resonance Imaging Assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance Imaging
Description: Magnetic resonance Imaging Assessment
Study: NCT02356094

Intervention type: PROCEDURE
Intervention: Pentacam
Description: Corneal topography using Scheimpflug Pentacam examination

Intervention type: PROCEDURE
Intervention: Pentacam
Description: Corneal topography using Scheimpflug Pentacam examination
Study: NCT04272008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Segesterone Acetate and Ethinyl Estradiol
Description: Annovera taken alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Segesterone Acetate and Ethinyl Estradiol
Description: Annovera taken alone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tampon
Description: Annovera with tampon use
Study: NCT01223898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasigna
Study: NCT01956045

Intervention type: OTHER
Intervention: Patient's capacity
Study: NCT02549222

Intervention type: OTHER
Intervention: Standard of Care

Intervention type: OTHER
Intervention: Standard of Care
Study: NCT02153346

Intervention type: OTHER
Group type: OTHER
Intervention: Valuation of lost productivity questionnaire
Description: A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.

Intervention type: OTHER
Group type: OTHER
Intervention: Work productivity and activity impairment questionnaire
Description: A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
Study: NCT01710527

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin 500mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin 500mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION

Intervention type: DRUG
Group type: OTHER
Intervention: Glucophage 500mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION

Intervention type: DRUG
Group type: OTHER
Intervention: Glucophage 500mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
Study: NCT03207945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01819987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet computer
Description: Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailing information
Description: Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
Study: NCT01911312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal-aided muscle stimulation
Description: Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Temperature Stimulation
Description: Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
Study: NCT04220112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-Time Functional Magnetic Resonance Imaging (RT-fMRI)
Description: RT-fMRI neurofeedback targeting down-regulation of the amygdala

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: RT-fMRI with feedback non-contingently tied to their activation patterns (activation patterns from a prior participant)
Study: NCT03208114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receiving written information on breast milk substitute
Description: Receiving written information on breast milk substitute
Study: NCT01822535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride
Description: Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
Study: NCT02278614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2347
Description: T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalacom
Description: Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
Study: NCT04890587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL8326 tablets
Description: Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
Study: NCT03365141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 0.4mg/cc
Description: * Intralesional injection of dilute triamcinolone acetonide with 2% lidocaine (400mg/20 mL) would be performed to reduce pain when injecting the drug.~* Once weekly, for a total of 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy (NBUVB or excimer laser)
Description: NBUVB or excimer laser treatment weekly

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy (NBUVB or excimer laser)
Description: NBUVB or excimer laser treatment weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tacrolimus
Description: Application of topical tacrolimus ointment twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus
Description: Application of topical tacrolimus ointment twice a day
Study: NCT02366767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic closed-loop insulin delivery
Description: Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Threshold suspend
Study: NCT01999218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg
Description: Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimerpiride
Description: Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Ertugliflozin
Description: Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Glimepiride
Description: Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Glimepiride
Description: Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Open label, oral, once daily, rescue medication as required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Open label, oral, once daily, rescue medication as required.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Open label, oral, once daily, rescue medication as required.
Study: NCT04847895

Intervention type: DRUG
Intervention: Lucentis
Description: There is no treatment allocation. Patients administered Lucentis by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT01457677

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo to RO4995819 oral once daily for 6 weeks
Study: NCT02329561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol extended release 200 mg
Description: Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CP/T
Description: Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CP/T
Description: Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
Study: NCT04006249

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: dental probes
Description: Measurement of the depth of the periodontal pockets and clinical loss
Study: NCT01531374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Study: NCT03331679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: 2 Weeks of High Intensity Interval Training on a Cycle ergometer
Study: NCT03445572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard supportive care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Perform MSB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Perform IK meditation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03652844

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AAM
Description: Subcutaneous injection procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AAM
Description: Subcutaneous injection procedure
Study: NCT01500629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-1266-7
Description: Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-1266-7
Description: Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-1266-6 (placebo)
Description: Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
Study: NCT01457677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4995819
Description: 5 mg oral once daily for 6 weeks
Study: NCT03713476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor task training
Description: motor task specific training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor task training
Description: motor task specific training
Study: NCT04970732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gum chewing
Description: The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
Study: NCT01457677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4995819
Description: 15 mg oral once daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4995819
Description: 30 mg oral once daily for 6 weeks
Study: NCT01500629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-1266-6 (placebo)
Description: Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
Study: NCT02902965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly~Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects \>75 years of age.~Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter.
Study: NCT02097407

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group C : Saline + propofol group
Description: All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group D : Dexmedetomidine + propofol group
Description: All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment.
Study: NCT01051050

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mandatory use of surgery wiki
Description: Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Voluntary use of the surgery wiki
Description: Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
Study: NCT01859533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neopuff
Description: * Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).~* Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).
Study: NCT02658747

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study: NCT03889210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVMN Ketone
Description: Water-based, flavoured sport beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water, stevia, malic acid, and thickening agent
Study: NCT00777530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib (SKI-606)
Study: NCT03222830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: personal embryo transfer
Description: According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle .
Study: NCT04134130

Intervention type: DRUG
Group type: OTHER
Intervention: Degarelix 120 MG [Firmagon]
Description: Two doses of degarelix, 240 mg, subcutaneously once, at study start.

Intervention type: DRUG
Group type: OTHER
Intervention: Degarelix 120 MG [Firmagon]
Description: Two doses of degarelix, 240 mg, subcutaneously once, at study start.

Intervention type: DRUG
Group type: OTHER
Intervention: Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector
Description: Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone Undecanoate
Description: One dose 1000 mg testosterone once, after 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone Undecanoate
Description: One dose 1000 mg testosterone once, after 3 weeks.
Study: NCT03693963

Intervention type: DEVICE
Group type: OTHER
Intervention: Serranator
Description: The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
Study: NCT04205851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIN-1901
Description: KIN-1901 is a fully human monoclonal antibody (mAb).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline